D\u00fcnyan\u0131n en \u00f6l\u00fcmc\u00fcl enfeksiyonlar\u0131ndan biri olan t\u00fcberk\u00fcloz (TB) tedavisinde, Johns Hopkins Medicine\u2019da ger\u00e7ekle\u015ftirilen \u00e7\u0131\u011f\u0131r a\u00e7an bir ara\u015ft\u0131rma yeni bir umut \u0131\u015f\u0131\u011f\u0131 oldu. Nature Communications dergisinde yay\u0131mlanan \u00e7al\u0131\u015fmada, kanser tedavisi i\u00e7in klinik denemelerde olan navitokslaks adl\u0131 ilac\u0131n, geleneksel TB tedavisinin etkinli\u011fini art\u0131rd\u0131\u011f\u0131 ortaya kondu. Bu ila\u00e7, h\u00fccrelerin \u00f6l\u00fcm \u015feklini de\u011fi\u015ftirerek, akci\u011fer hasar\u0131n\u0131 s\u0131n\u0131rland\u0131r\u0131yor ve bakterinin yay\u0131l\u0131m\u0131n\u0131 engelliyor. Fareler \u00fczerinde yap\u0131lan deneylerde elde edilen veriler, antibiyotiklerle birlikte kullan\u0131lan bu konak\u00e7\u0131 odakl\u0131 terapilerin, hastalar\u0131n iyile\u015fme s\u00fcre\u00e7lerini h\u0131zland\u0131rmada ve tedavi s\u00fcrelerini k\u0131saltmada etkili olabilece\u011fine i\u015faret ediyor.<\/p>\n
T\u00fcberk\u00fcloz, Mycobacterium tuberculosis adl\u0131 bakterinin yol a\u00e7t\u0131\u011f\u0131, d\u00fcnya \u00e7ap\u0131nda ciddi bir sa\u011fl\u0131k problemi olmaya devam ediyor. 2023 y\u0131l\u0131nda yakla\u015f\u0131k 10.8 milyon yeni vaka ve 1.25 milyon \u00f6l\u00fcm\u00fcn ger\u00e7ekle\u015fti\u011fi TB\u2019de standart tedaviler genellikle en az alt\u0131 ay s\u00fcren \u00e7oklu antibiyotik kombinasyonlar\u0131n\u0131 i\u00e7eriyor. Bu uzun ve zorlu tedavi s\u00fcreci, ila\u00e7 direnci, hasta uyumsuzlu\u011fu ve kal\u0131c\u0131 akci\u011fer hasar\u0131 riskini beraberinde getiriyor. Johns Hopkins ekibi, enfeksiyon s\u0131ras\u0131ndaki akci\u011fer dokusu hasar\u0131n\u0131n biyolojik temelini inceleyerek, enfekte h\u00fccrelerin \u00f6l\u00fcm bi\u00e7imini manip\u00fcle etmenin hastal\u0131\u011f\u0131n \u015fiddetini azaltabilece\u011fini ortaya koymak istedi.<\/p>\n
V\u00fccut, enfekte h\u00fccreleri y\u00f6netmek i\u00e7in \u00e7e\u015fitli programlanm\u0131\u015f h\u00fccre \u00f6l\u00fcm\u00fc yollar\u0131n\u0131 kullan\u0131r. TB\u2019nin erken evresinde apoptozis ad\u0131 verilen, ba\u011f\u0131\u015f\u0131kl\u0131k tepkisini \u00e7ok az tetikleyen kontroll\u00fc h\u00fccre \u00f6l\u00fcm\u00fc, bakterinin yay\u0131l\u0131m\u0131n\u0131 s\u0131n\u0131rland\u0131r\u0131r. Ancak hastal\u0131k ilerledik\u00e7e, M. tuberculosis bakterisi konak\u00e7\u0131 h\u00fccrelerin \u00f6l\u00fcm \u015feklini nekroz y\u00f6n\u00fcne kayd\u0131r\u0131r. Nekroz, h\u00fccrelerin kontrols\u00fczce par\u00e7alanmas\u0131 ve iltihapl\u0131 materyallerin s\u0131z\u0131nt\u0131s\u0131 ile karakterizedir; bu s\u00fcre\u00e7 akci\u011fer dokusuna zarar verir ve bakterinin v\u00fccutta daha h\u0131zl\u0131 yay\u0131lmas\u0131n\u0131 sa\u011flar.<\/p>\n
Bu patojen odakl\u0131 h\u00fccre s\u00fcreci y\u00f6nlendirmesinde Bcl-2 ailesi proteinleri merkezi rol oynar. Enfekte h\u00fccrelerde aktifle\u015fen ve apoptozisi engelleyen bu proteinler, bakterinin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden ka\u00e7mas\u0131na ve nekrotik, bakterinin ya\u015fam ko\u015fullar\u0131na uygun mikro ortamlar olu\u015fturmas\u0131na olanak tan\u0131r. Ara\u015ft\u0131rma ekibinden Dr. Medha Singh, bu molek\u00fcler engellemenin a\u015f\u0131lmas\u0131 durumunda apoptozisin artt\u0131\u011f\u0131n\u0131 ve hastal\u0131k ilerlemesinin \u00f6nlenebilece\u011fini ileri s\u00fcrd\u00fc.<\/p>\n
Kanser tedavisinde geli\u015ftirilen ve Bcl-2 proteinlerini hedef alan navitokslaks, rifampisin, izoniazid ve pirazinamid (RHZ) adl\u0131 standart antibiyotik kombinasyonu ile birlikte fare modelinde kullan\u0131ld\u0131. D\u00f6rt hafta s\u00fcren tedavi s\u00fcrecinde navitokslaks ile birlikte RHZ alan farelerin akci\u011ferlerindeki nekrotik lezyonlar %40 oran\u0131nda azald\u0131. Ayr\u0131ca bu farelerde bakterinin dalak gibi di\u011fer organlara yay\u0131l\u0131m\u0131 da anlaml\u0131 \u015fekilde engellendi, bu da tedavinin konak\u00e7\u0131 savunmas\u0131n\u0131 g\u00fc\u00e7lendirdi\u011fini g\u00f6sterdi.<\/p>\n
\u00c7al\u0131\u015fmada ileri canl\u0131 g\u00f6r\u00fcnt\u00fcleme teknikleri, \u00f6zellikle pozitron emisyon tomografisi (PET), tedavi s\u0131ras\u0131nda akci\u011ferde apoptotik aktivitelerin ve fibrozisin dinamik olarak \u00f6l\u00e7\u00fclmesini sa\u011flad\u0131. Navitokslaks tedavisi, pulmoner dokularda apoptotik aktiviteyi yakla\u015f\u0131k iki kat art\u0131r\u0131rken, akci\u011fer fibrozisini %40 oran\u0131nda azaltt\u0131. Bu sonu\u00e7lar, hastal\u0131\u011f\u0131n yol a\u00e7t\u0131\u011f\u0131 patolojik yeniden \u015fekillenmenin azald\u0131\u011f\u0131 ve akci\u011fer dokusunun daha iyi korundu\u011funu simgeliyor. \u00c7al\u0131\u015fman\u0131n ortak yazar\u0131 ve radyoloji uzman\u0131 Dr. Laurence Carroll, PET g\u00f6r\u00fcnt\u00fclemenin yaln\u0131zca ara\u015ft\u0131rma a\u015famas\u0131nda de\u011fil, ayn\u0131 zamanda klinik tedavi s\u0131ras\u0131nda konak\u00e7\u0131 yan\u0131tlar\u0131n\u0131 izlemek i\u00e7in de bir biyobelirte\u00e7 olarak kullan\u0131lma potansiyeline dikkat \u00e7ekti.<\/p>\n
Navitokslaks\u0131n M. tuberculosis \u00fczerinde do\u011frudan antibakteriyel etkisi olmad\u0131\u011f\u0131 belirlendi. \u0130lac\u0131n faydas\u0131, konak\u00e7\u0131 yan\u0131t\u0131n\u0131 mod\u00fcle etmesinden, yani enfekte h\u00fccreleri nekrozdan apoptozis y\u00f6n\u00fcne kayd\u0131rarak, antibiyotiklerin etkinli\u011fini art\u0131rmas\u0131ndan kaynakland\u0131. Bu mekanizma, bakteriyel y\u00fck\u00fcn azalt\u0131lmas\u0131nda 16 katl\u0131k bir iyile\u015fmeye yol a\u00e7t\u0131. Dolay\u0131s\u0131yla konak\u00e7\u0131 kaynakl\u0131 tedaviler, TB ile m\u00fccadelede d\u00fc\u015f\u00fck diren\u00e7 geli\u015fimi riskiyle birlikte hastal\u0131\u011f\u0131n \u00e7ift y\u00f6nl\u00fc kontrol\u00fcn\u00fc sa\u011flayabilir.<\/p>\n
Johns Hopkins\u2019dan k\u0131demli ara\u015ft\u0131rmac\u0131 ve pediatrik enfeksiyon uzman\u0131 Dr. Sanjay Jain, benzer tedavi stratejilerinin ABD\u2019de yayg\u0131n olan Staphylococcus aureus ve t\u00fcberk\u00fcloza ba\u011fl\u0131 olmayan mikobakteriler gibi di\u011fer kronik bakteriyel enfeksiyonlarda da i\u015fe yarayabilece\u011fini belirtti. Bu da Bcl-2 proteinlerini hedef alan yakla\u015f\u0131mlar\u0131n yaln\u0131zca TB restriksiyonlar\u0131yla s\u0131n\u0131rl\u0131 kalmay\u0131p, inflamasyon kaynakl\u0131 doku hasar\u0131n\u0131n \u00f6nlenmesinde geni\u015f uygulama alanlar\u0131 bulabilece\u011fini g\u00f6sterdi.<\/p>\n
Ara\u015ft\u0131rman\u0131n hayvan modellerinden insan hastalar\u0131na ge\u00e7i\u015f s\u00fcreci zorlu olacak; ancak Johns Hopkins ekibi, Enfeksiyon ve \u0130nflamasyon G\u00f6r\u00fcnt\u00fcleme Ara\u015ft\u0131rma Merkezi\u2019nde geli\u015ftirdikleri ya\u015fam boyu izlenebilir non-invaziv g\u00f6r\u00fcnt\u00fcleme teknikleri sayesinde klinik denemeleri h\u0131zland\u0131rmay\u0131 planl\u0131yor. Bu teknolojiler, tedavi etkinli\u011fine dair erken ve g\u00fcvenilir bilgiler sa\u011flayarak ki\u015fiselle\u015ftirilmi\u015f tedavi stratejilerinin geli\u015ftirilmesine olanak tan\u0131yacak.<\/p>\n
Klinik ba\u015far\u0131 elde edilirse, navitokslaks veya benzeri konak\u00e7\u0131 y\u00f6nelimli ajanlar mevcut antibiyotik rejimlerine entegre edilerek tedavi s\u00fcrelerini k\u0131saltabilir, n\u00fcks oranlar\u0131n\u0131 azaltabilir ve TB sonras\u0131 kronik akci\u011fer hastal\u0131klar\u0131n\u0131 engelleyebilir. Bu, halen zorlu bir hastal\u0131k olarak kabul edilen t\u00fcberk\u00fcloz tedavisinde k\u00f6kl\u00fc bir de\u011fi\u015fim anlam\u0131na gelecek ve hastal\u0131kla konak\u00e7\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k etkile\u015fimlerini yeniden tan\u0131mlayacak.<\/p>\n
Ara\u015ft\u0131rma, TB\u2019de artan ila\u00e7 direnci sorununa da yeni bir \u00e7\u00f6z\u00fcm \u00f6neriyor. Konak\u00e7\u0131 yan\u0131t\u0131n\u0131n d\u00fczenlenmesi yoluyla antibiyotik etkinli\u011finin art\u0131r\u0131lmas\u0131, diren\u00e7li su\u015flarla m\u00fccadelede tamamlay\u0131c\u0131 bir strateji olu\u015fturuyor. Ayr\u0131ca, kronik akci\u011fer skarla\u015fmas\u0131 ve post-TB akci\u011fer hastal\u0131klar\u0131n\u0131n \u00f6nlenmesiyle, milyonlarca hastan\u0131n ya\u015fam kalitesi ve uzun vadeli solunum fonksiyonlar\u0131 iyile\u015ftirilebilir.<\/p>\n
Johns Hopkins ara\u015ft\u0131rmac\u0131lar\u0131 enfeksiyon hastal\u0131klar\u0131, radyoloji, imm\u00fcnoloji ve molek\u00fcler biyoloji alanlar\u0131nda uzmanla\u015fm\u0131\u015f disiplinler aras\u0131 kadrolarla bu \u00e7al\u0131\u015fmay\u0131 ger\u00e7ekle\u015ftirdi. Bu g\u00fc\u00e7l\u00fc i\u015f birli\u011fi, molek\u00fcler d\u00fczeyde konak\u00e7\u0131-patogen etkile\u015fiminin anla\u015f\u0131lmas\u0131 ve manip\u00fcle edilmesi ile daha g\u00fcvenli ve etkili tedavilerin geli\u015ftirilmesine y\u00f6nelik umut vaat ediyor.<\/p>\n
Ulusal Sa\u011fl\u0131k Enstit\u00fcleri\u2019nin (NIH) fon deste\u011fiyle ger\u00e7ekle\u015ftirilen bu temel ve klinik ara\u015ft\u0131rma, federal yat\u0131r\u0131mlar\u0131n milyonlarca hayat\u0131 kurtarabilecek yeniliklerin \u00f6n\u00fcn\u00fc a\u00e7t\u0131\u011f\u0131n\u0131 bir kez daha g\u00f6sterdi. T\u00fcberk\u00fclozun \u00f6zellikle d\u00fc\u015f\u00fck ve orta gelirli \u00fclkelerde yaratt\u0131\u011f\u0131 a\u011f\u0131r y\u00fck g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, konak\u00e7\u0131 merkezli bu yakla\u015f\u0131m, akci\u011fer sa\u011fl\u0131\u011f\u0131n\u0131 koruyarak daha eri\u015filebilir ve etkin tedaviler sunma vaadiyle global sa\u011fl\u0131kta devrim yaratabilir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Resim Credits<\/strong>: Anahtar Kelimeler<\/strong>: D\u00fcnyan\u0131n en \u00f6l\u00fcmc\u00fcl enfeksiyonlar\u0131ndan biri olan t\u00fcberk\u00fcloz (TB) tedavisinde, Johns Hopkins Medicine\u2019da ger\u00e7ekle\u015ftirilen \u00e7\u0131\u011f\u0131r a\u00e7an bir ara\u015ft\u0131rma yeni bir umut \u0131\u015f\u0131\u011f\u0131 oldu. Nature Communications dergisinde yay\u0131mlanan \u00e7al\u0131\u015fmada, kanser tedavisi i\u00e7in klinik denemelerde olan navitokslaks adl\u0131 ilac\u0131n, geleneksel TB tedavisinin etkinli\u011fini art\u0131rd\u0131\u011f\u0131 ortaya kondu. Bu ila\u00e7, h\u00fccrelerin \u00f6l\u00fcm \u015feklini de\u011fi\u015ftirerek, akci\u011fer hasar\u0131n\u0131 s\u0131n\u0131rland\u0131r\u0131yor ve bakterinin yay\u0131l\u0131m\u0131n\u0131…<\/p>\n","protected":false},"author":1,"featured_media":3360,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[1955,1952,1954,1953,1956],"tmauthors":[],"class_list":{"0":"post-3359","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-bcl-2-protein-inhibitorleri-ve-tb","9":"tag-deneysel-kanser-ilaci-tb-tedavisinde","10":"tag-konakci-odakli-terapiler-tuberkulozda","11":"tag-navitokslaks-ile-tuberkuloz-tedavi-iyilestirme","12":"tag-tuberkulozda-hucre-olumu-manipulasyonu"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Deneysel-Kanser-Ilaci-TB-Tedavisini-Iyilestiriyor-1745245774.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3359"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3359\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3360"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3359"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nT\u00fcberk\u00fcloz tedavisinde konak\u00e7\u0131 y\u00f6nelimli terapi olarak navitokslaks kullan\u0131m\u0131yla apoptosis (programlanm\u0131\u015f h\u00fccre \u00f6l\u00fcm\u00fc) art\u0131r\u0131larak akci\u011fer hasar\u0131n\u0131n azalt\u0131lmas\u0131 ve bakteriyel yay\u0131l\u0131m\u0131n \u00f6nlenmesi.<\/p>\n
\nAdding Navitoclax to Standard TB Treatment Enhances Cell Death, Reduces Lung Scarring, and Improves Bacterial Clearance<\/p>\n
\n27 Mart 2025<\/p>\n
\nNature Communications
\nD\u00fcnya Health Organization TB Fact Sheet<\/p>\n
\nSingh et al., Nature Communications 2025<\/p>\n
\nT\u00fcberk\u00fcloz, Bakteriyel enfeksiyonlar, Hayvan ara\u015ft\u0131rmas\u0131, Akci\u011ferler, Klinik ara\u015ft\u0131rma, H\u00fccre apoptozu, \u0130la\u00e7 \u00e7al\u0131\u015fmalar\u0131, Pozitron emisyon tomografisi, Klinik denemeler<\/p>\n","protected":false},"excerpt":{"rendered":"